Replies to post #514235 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

The FDA and NIH work very closely together. Highly reputable licensed professionals have vetted the immunotherapy research of Dr. Liau, I would recommend that you research and study for yourself the recent 590 million dollar grant that was awarded to UCLA. The U.S. government NIH grant is funded by tax dollars and is public record for anyone who wants to see it. Many independent physicians have reviewed the immunotherapy work of Dr. Liau. Verify it for yourself.

The NIH peer-reviewed grant is the source of funding being used today to dose patients with DCVax-L and Keytruda.

Department of Neurosurgery Chair Linda M. Liau, MD, PhD, MBA, was a leading recipient of NIH grants – No. 3 in the nation within the discipline.

“It's the stamp of approval from the NIH, because these types of grants are so rigorously peer-reviewed,” Dr. Liau says. “People get funded based on the strength of the science and that, itself, is very powerful in terms of showing that our research is scientifically valid and meaningful and hopefully will lead to future treatments.”

https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

Dr. Pazdur, FDA:
https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext

[SkyLimit2022]

That is correct: The global DCVax P3 trial was designed and led by two world-renowned CLINICAL TRIAL EXPERTS.

Dr. Linda Liau is a world-renowned neuro-oncologist, surgeon, and educator at UCLA where she is also the chair of the department of neurosurgery. As her paper on DCVax moves through the independent peer review process, it is interesting to note that she was once the editor-in-chief of a neuro-oncology medical journal.

https://www.uclahealth.org/providers/linda-liau

Across the pond from Dr. Liau, Dr. Ashkan was the chief investigator of the DCVax trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.

https://www.kcl.ac.uk/people/keyoumars-ashkan

[Dr Bala]

Totally nonsensical post.

[SkyLimit2022]

Research these facts:

Dr. Liau is backed by FDA-NIH. DCVax would not exist without the NIH funding that led to its development. NIH is today funding the DCVax doses going into patients’ arms in the Keytruda study. FDA-NIH has been backing Dr. Liau for years.

Dr. Ashkan is the chief of the clinical trials unit at Kiing’s College and Dr. Ashkan is an advisor to the U.K. government. MHRA has already demonstrated its support for the development of the DCVax platform technology and that support has only strengthened in recent months. MHRA values Dr. Ashkan’s work and supports DCVax.

https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter

https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016

https://www.uclahealth.org/providers/linda-liau

https://www.kcl.ac.uk/people/keyoumars-ashkan

https://virtualtrials.org/dcvax.cfm